Spyre Therapeutics, Inc. Ratios

Ratios Dec2014 Dec2015 Dec2016 Dec2017 Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
EBT Margin -185.59%-468.06%-522.46%-1,135.67%-350.39%-3,604.59%-38,241.08%
EBIT Margin -185.95%-473.34%-531.72%-1,165.72%-350.33%-3,640.23%-27,347.97%
EBITDA Margin -185.95%-473.34%-531.72%-1,165.72%-350.33%-3,640.23%-27,347.97%
Operating Margin -185.95%-473.34%-531.72%-1,165.72%-350.33%-3,640.23%-27,347.97%
Net Margin -189.37%-468.84%-523.27%-1,135.67%-351.14%-3,598.75%-38,238.15%
FCF Margin -183.89%-411.67%-484.80%-836.28%-289.71%-3,442.77%-11,276.52%
Efficiency
Assets Average 52.86M61.57M66.91M80.46M122.40M135.77M90.53M206.50M475.17M
Equity Average -16.84M20.38M56.65M58.88M63.75M99.96M111.89M67.12M117.16M350.91M
Invested Capital -11.47M-22.21M62.97M50.34M67.43M60.08M139.83M83.94M50.30M185.41M542.88M
Asset Utilization Ratio 0.090.080.060.140.030.00
Leverage & Solvency
Debt to Equity 0.010.05
Debt Ratio 0.000.04
Equity Ratio -0.570.940.900.870.720.870.760.710.540.85
Valuation
Enterprise Value -2.62M-33.06M-5.08M39.75M104.96M149.50M230.99M141.14M-28.04M-252.14M594.23M
Market Capitalization 58.42M90.05M179.48M221.45M377.26M234.27M27.67M87.13M1,197.32M
Return Ratios
Return on Sales -1.86%-4.68%-5.22%-11.36%-3.51%-35.99%-382.38%
Return on Capital Employed -0.45%-0.49%-0.80%-1.29%-0.77%-0.57%-1.12%-1.39%-0.50%
Return on Invested Capital -1.26%-2.06%
Return on Assets -0.41%-0.44%-0.66%-0.97%-0.66%-0.48%-0.93%-1.64%-0.44%
Return on Equity 0.67%-1.06%-0.48%-0.75%-1.23%-0.81%-0.59%-1.25%-2.89%-0.59%